COMMON MAPS
Map version new-york activity top-down
Main site Contact
Menu
↑ parent activity group ·
research dossier

NEW YORK EYE AND EAR INFIRMARY FOUNDATION

NEW YORK, NY · EIN 134012469 · Form 990PF · FY2025 · NTEE T20Z · Philanthropy & Grantmaking · Small ($100K-$1M)
revenue
$886K
expenses
$209K
net assets
$11.8M
employees
profile · synthesized from sources

The New York Eye and Ear Infirmary Foundation is a grantmaking organization that supports research into eye and ear illnesses, with a focus on advancing treatments and cures. It funds medical institutions and research initiatives in New York and nationally, including work on retinitis pigmentosa, Stargardt disease, and general ophthalmic and ENT research. The foundation operates in New York, NY.

named programs · 4 · from sources

What they call their work

Dr. Tsang Fund - Retinitis Pigmentosa Research
Supports research on retinitis pigmentosa at Columbia University through the Dr. Tsang Fund
Eye and ENT Research Support
Provides funding to The New York Eye and Ear Infirmary for research into eye and ear illnesses to improve treatment methods and find cures
Medical Institution Research Grants
Provides funding to top-ranked medical schools including Weill Cornell Medicine and Columbia University for ophthalmic and ENT research
Stargardt Disease Research
Funds research into the mechanisms of Stargardt disease using zebrafish models, in partnership with the Foundation Fighting Blindness
activities · 1 group

What they do

  • Vision Research Funding 3 activities
    • Funding Stargardt disease research using zebrafish models
      Funds research to identify the mechanisms of Stargardt disease through the use of zebrafish models.
    • Funding research into eye and ENT illnesses
      Funds research to develop improved treatments or cures for eye and ear, nose, and throat (ENT) illnesses, including support for studies at a top-ranked medical and graduate school.
    • Funding retinitis pigmentosa research through the Dr. Tsang Fund
      Funds research on retinitis pigmentosa via the Dr. Tsang Fund.
financials · form 990PF · fy2025
revenue
Total revenue$886K
Contributions & grants
Program service revenue
Investment income$409K46%
Other revenue$477K
expenses
Total expenses$209K
Program expenses
Admin / overhead
Fundraising
Salaries & benefits$88K
Grants paid out$895K
balance sheet
Total assets$11.81M
Cash
Investments
Liabilities
Net assets$11.81M
6 years on record · 2020–2025 · YoY revenue -1.0%
leadership · form 990 part vii · fy2025

Who runs it

paid leadership · 5
NameTitleHours/wkCompensation
CHARLIE FIGLIOZZI TREASURER & TRUSTEE 6 $33K
PETER CROWLEY PRESIDENT 6 $33K
EDWARD NOWAK TRUSTEE 1 $8K
JAMES KEMPNER TRUSTEE 1 $8K
SORRELL MATHES TRUSTEE 1 $8K
relationships · 4

Who they work with

  • COLUMBIA UNIVERSITY IRVING MC Partner — Receives funding for retinitis pigmentosa research via the Dr. Tsang Fund.
  • FOUNDATION FIGHTING BLINDNESS INC Partner — Receives funding for research on Stargardt disease using zebrafish models.
  • THE NEW YORK EYE AND EAR INFIRMARY Partner — Receives funding to support research on eye and ENT illnesses.
  • WEILL CORNELL MEDICINE Partner — Receives funding to support research at a top-ranked medical institution.
strategies · 2

How they approach the work

Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.

  • Research Funding for Medical Innovation
    methodology: research-funding-for-medical-innovation
    By funding scientific research into eye and ear, nose, and throat (ENT) illnesses, we advance the development of improved treatments and potential cures, because targeted investment accelerates discovery and clinical translation.
  • Zebrafish Model Research for Disease Mechanisms
    methodology: zebrafish-model-research
    By using zebrafish models to study Stargardt disease, we uncover fundamental biological mechanisms of vision loss, because zebrafish share genetic and physiological traits with humans that enable rapid, scalable, and ethically feasible research to inform future therapies.